In Vitro and In Vivo Antihyperglycemic Effects of New Metabiotics from .

The increasing incidence of diabetes has prompted the need for new treatment strategies, including natural products that reduce glycemia values. This work examined the in vitro and in vivo antihyperglycemic effects of new metabiotics derived from extracts. The metabiotics were obtained from 100% , and two other products, CARDIO and GLYCEMIC, from Anoom Laboratories SRL, which contain other microbial species related to . Our in vitro investigations (simulations of the microbiota of patients with type 2 diabetes (T2D)) demonstrated that extracts modulate the microbiota, normalizing its pattern. The effects were further tested in vivo, employing a mouse model of T2D. The tested extracts decreased glycemia values compared to the control and modulated the microbiota. The metabiotics had positive effects on T2D in vitro and in vivo, suggesting their potential to alleviate diabetes-associated microbiota dysbiosis.